Sab Biotherapeutics, Inc. · NASDAQ:SABS

Sab Biotherapeutics — Investor Presentation (September 2022)

39 slides from Sab Biotherapeutics's investor presentation, Sep 23, 2022

  1. Slide 1: Advancing a Powerful New Class of Immunotherapeutic Antibodies

    ADVANCING A POWERFUL NEW CLASS OF IMMUNOTHERAPEUTIC ANTIBODIES September 2022 © 2022 SAB BIOTHERAPEUTICS, INC. EXHIBIT 99.1

  2. Slide 2: Experienced Management Team

    Experienced Management Team Christoph Bausch, PhD, MBA EVP & CHIEF OPERATING OFFICER 20+ years research and discovery, biomanufacturing, business development, and platform technology commercialization MilliporeSigma (Merck KGaA) Stowers Institute for Medical Research Postdoc Eddie J. Sullivan, PhD P

  3. Slide 3: Advancing a New Class of Immunotherapies

    Advancing a New Class of Immunotherapies Vertical integration enables rapid, scalable development of multi-targeted products Robust, growing clinical-stage pipeline spanning multiple therapeutic areas Established proof-of-concept through funded programs & partnerships totaling ~$200MM Strong corpora

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements 4 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (“SAB”) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete

  5. Slide 5: Versatile Antibody Platform with Ability to Capture Multiple Modalities

    Versatile Antibody Platform with Ability to Capture Multiple Modalities 5 Human Antibody Discovery & Product Development Engine, New Source for Novel Treatments Monoclonal Antibody Discovery –Larger volume of antibodies –Greater diversity; higher affinity –Robust (ruminant) immune response –Fully-hu

  6. Slide 6: DiversitAb Platform

    DiversitAb™ Platform Advancing a new class of fully-human polyclonal Tc bovine-derived antibodies without the need for human serum ANTIGEN PATHOGEN TC BOVINE™ HYPERIMMUNIZATION HUMAN ANTIBODIES PURIFICATION TARGETED HIGH-POTENCY IMMUNOTHERAPY Reliable, controlled, consistent production of diverse, h

  7. Slide 7: Polyclonals: Broader Spectrum Efficacy

    FDA: CENTER FOR DRUG EVALUATION & RESEARCH (CDER) FDA: CENTER FOR BIOLOGICS EVALUATION & RESEARCH (CBER) pAbs TARGET Monoclonal Approach Highly-targeted with specific activity Iterative Ab identification and selection process Selected and cloned in vitro May promote escape mutants via selective pres

  8. Slide 8: Demonstrated Human Safety and Efficacy in Multi-Dosing Regimen

    High-dose therapy resulted in improved clinical parameters associated with reduced M. hominis burden following two subsequent infections JARED N SILVER, CAMERON D ASHBAUGH, JACOB J MILES, HUA WU, GREGORY T MARECKI, JOYCE K HWANG, JIN-AN JIAO, MARK ABRAMS, EDDIE J SULLIVAN, DUANE R WESEMANN, DEPLOYME

  9. Slide 9: DiversitAb Platform is Clinically Validated Across Several Targets

    DiversitAb™ Platform is Clinically Validated Across Several Targets Referenced Trials: Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants – Full Text View - ClinicalTrials.gov Study of SAB-176 in Healthy Adult Participants - Full Text View - ClinicalTrials.gov Safety, Tole

  10. Slide 10: Selected Pipeline Programs

    SELECTED PIPELINE PROGRAMS © 2022 SAB BIOTHERAPEUTICS, INC.

  11. Slide 11: Robust Biologic Pipeline with Broad Polyclonal Therapeutic Reach

    Robust Biologic Pipeline with Broad Polyclonal Therapeutic Reach © 2022 SAB BIOTHERAPEUTICS, INC.

  12. Slide 12: Clinical Development Programs: Focus Over the Next 4+ Years

    Clinical Development Programs: Focus Over the Next 4+ Years SAB-195 IND (CDI, targeting H2 2023-H1 2024) SAB-176 2023-2024 flu season Phase 2b FPI SAB-142 IND (T1D) SAB-142 Phase 1/POBA FPI SAB-195 Phase 1/POBA FPI SAB-195 Phase1/POBA topline SAB-176 2023-2024 flu season Phase 2b topline SAB

  13. Slide 13: SAB-195: Clostridioides difficile Infections: Fast to Proof-of-Concept

    SAB-195: Clostridioides difficile Infections: Fast to Proof-of-Concept © 2022 SAB BIOTHERAPEUTICS, INC.

  14. Slide 14: Clostridioides difficile Infection (CDI) Overview and Burden

    Clostridioides difficile Infection (CDI) is a bacterial infection of the large intestine (colon). A spectrum of clinical disease ranges from mild diarrhea to severe. CDI is characterized by abdominal pain, fever, diarrhea, nausea, and vomiting. Complications of severe CDI include kidney failure, tox

  15. Slide 15: Value Proposition: SAB-195 Key Differentiators

    Value Proposition: SAB-195 Key Differentiators First-in-class fully human polyclonal antibody treatment with dual mechanism of action designed to treat severe CDI and reduce CDI recurrence in high-risk patients First-in-class fully human polyclonal antibody treatment Only treatment with dual mode of

  16. Slide 16: SAB-195 Preclinical Data

    SAB-195 Preclinical Data Tc bovine Immunized with Antigen Fusion Proteins Constructed from Receptor Binding Domain of C. diff Toxin A (TcdA), C. diff Toxin B (TcdB)(630) and (TcdB)(027) and Binary Toxin (CDT) Tc bovine-derived anti-quadrivalent toxin hIgG provided 90% to 100% protection in hamsters

  17. Slide 17: SAB-195: Clinical Development Plan

    SAB-195: Clinical Development Plan CDI: Two Indications Phase 1/Proof of Biological Activity (POBA) Phase 1 in adult healthy volunteers (HVs), followed by subjects meeting high-risk criteria and patients with CDI Phase 2b - 3: Adult patients with moderate to severe CDI at risk for recurrent CDI STUD

  18. Slide 18: SAB-195 Development Timelines

    SAB-195 Development Timelines Preclinical/ IND Enabling IND Filing Phase 1 in Healthy Volunteers Topline Data Phase 1/Proof of Biological Activity Phase 2b in Target Patient Population Phase 2b Topline 2022-2023 H2 2023 -H1 2024 2024 2024 2024 - 2025 H2 2025 © 2022 SAB BIOTHERAPEUTICS, INC.

  19. Slide 19: SAB-176: First-In-Class Biologic Anti-Influenza Treatment

    SAB-176: First-In-Class Biologic Anti-Influenza Treatment © 2022 SAB BIOTHERAPEUTICS, INC.

  20. Slide 20: Unmet Need of Seasonal Influenza

    Unmet Need of Seasonal Influenza Devastating health and economic impacts Estimated 30,000 - 50,000 deaths/year U.S. with 290,000 - 650,000 globally ~500,000 hospitalizations annually in U.S. Average US hospital stay: $8,000 - $9,000/day; 4-8 days/stay Often 30% - 70% failure rate for vaccine; vaccin

  21. Slide 21: Value Proposition: SAB-176 Key Differentiators

    Value Proposition: SAB-176 Key Differentiators First-in-class fully human polyclonal antibody treatment aimed to provide superior long-lasting efficacy for prophylaxis and management of influenza in patients at high-risk First and only biologic for management of influenza in high-risk patients Adapt

  22. Slide 22: Efficacy Against Mutational Drift

    B/Florida/04/2006 Challenge strain SOURCE:NEXTFLU AT HTTPS://NEXTFLU.ORG/VIC/12Y/ Antibodies produced to B/Phuket/3073/2013 protected against B/Florida/04/2006 2006 2017 B/Phuket/3073/2013 Vaccination strain Highly-Mutational Influenza Virus BYAM PHYLOGENIC TREE 100% Protection at All Dose Levels in

  23. Slide 23: Established Proof-of-Concept for SAB-176: Met Primary Endpoint in Phase 2a

    Established Proof-of-Concept for SAB-176: Met Primary Endpoint of Viral Load Reduction in Phase 2a Challenge Study Achieved Statistically Significant (p = 0.026) Reduction in Viral Load Mean Viral Load by Nasal Samples qRT-qPCR by Day Relative to Viral Challenge 23 Mean Total Symptom Score by Day Re

  24. Slide 24: SAB-176: Clinical Development Plan

    SAB-176: Clinical Development Plan Phase 1: Healthy Volunteers Planned Phase 2a Challenge Study: Healthy Volunteers Planned Phase 2b and Phase 3 Designs STUDY DESIGN Randomized, double-blind, placebo-controlled 27 healthy volunteers Single ascending dose study 1, 10, 25 and 50 mg/kg 60 total partici

  25. Slide 25: SAB-176 Development Timelines

    SAB-176 Development Timelines Study Startup Activities Phase 2b Study First Patient In Phase 2b Study Ongoing Phase 2b Topline Results Phase 3 Study First Patient In 2022-2023 Q4 2023 2023-2024 Influenza Season 2024 2025 © 2022 SAB BIOTHERAPEUTICS, INC.

  26. Slide 26: SAB-142: Type 1 Diabetes (T1D) Prevention

    SAB-142: Type 1 Diabetes (T1D) Prevention © 2022 SAB BIOTHERAPEUTICS, INC.

  27. Slide 27: Type 1 Diabetes High Unmet Medical Needs Drive High Level of Competition

    Disease-modifying treatments in late-stage development: >100 active interventional trials with small molecules, biologics, and cell therapies in Type 1 Diabetes Type 1 Diabetes High Unmet Medical Needs Drive High Level of Competition © 2022 SAB BIOTHERAPEUTICS, INC.

  28. Slide 28: Value Proposition: SAB-142 Key Differentiators

    Value Proposition: SAB-142 Key Differentiators First-in-class fully human polyclonal antibody treatment aimed to provide superior efficacy for delaying onset of clinical Stage 3 Type 1 Diabetes (T1D) First-in-class fully human polyclonal antibody treatment aimed to provide superior efficacy for dela

  29. Slide 29: SAB-142: Similar Activity to Approved Rabbit ATG

    SAB-142: Similar Activity to Approved Rabbit Anti-Thymocyte Globulin (ATG) Targets CD8 and Protects T-Regulatory Cells CD8 T Cells Treg Cells Live cells in CD8* gate Live CD4+CD25+Foxp3- Activated CD4 T Cells Live CD4+CD25+Foxp3- Naïve CD4 T Cells Live CD4+CD25+Foxp3- © 2022 SAB BIOTHERAPEUTICS, INC

  30. Slide 30: SAB-142 Preclinical Data Continued

    SAB-142 Preclinical Data Continued Major Subsets of Peripheral Blood Lymphocytes Changes in major subsets of peripheral blood lymphocytes (total lymphocytes. T and B cells, CD4+ and CD8+ T helpers and killers, respectively) following SAB-142 and ATG treatments. Red: 5 mg/kg ATG; Blue: 1 mg/kg SAB-14

  31. Slide 31: SAB-142: MoA Clinically Validated by 3rd Party Compound

    SAB-142: MoA Clinically Validated by 3rd Party Compound 31 p=0.00005 ATG vs Placebo Placebo *RABBIT ATG FROM SANOFI – NOT SAB-142 (HUMAN TC-BOVINE DERIVED ATG) Haller et al. Diabetes. 2019. June, 68(6): 1267-1276 EQUINE ATGAM-AF488 Tc Bovine Human-PB, Rabbit THYMO-AF488, Equine ATGAM-AF488 and Anti-

  32. Slide 32: SAB-142: Clinical Development Plan

    SAB-142: Clinical Development Plan Type 1 Diabetes (T1D) Phase 1-2: Early Onset T1D in Adults, followed by adults and adolescents at C-peptide interim analysis Phase 3: New and Recent Onset T1D in Adults and Children (Study 1) At Risk Adults and Children (Study 2) STUDY DESIGN Open-label Teplizumab

  33. Slide 33: SAB-142 Type 1 Diabetes Development Timelines

    SAB-142 Type 1 Diabetes Development Timelines Preclinical / IND Enabling IND Filing Phase 1 / Proof of Biological Activity in Adult Type 1 Diabetes Phase 1 / Proof of Biological Activity in Adult + Pediatric Type 1 Diabetes Phase 1 / Proof of Biological Activity in Topline 2022-2023 2024 2024 2025 2

  34. Slide 34: Summary

    Summary 34 Executive Management: Proven team with biotech startup, rapid drug development, and entrepreneurial experience. Platform: Innovative DiversitAb™ platform produces a new class of targeted fully-human, highly-potent polyclonal antibodies, with a broad efficacy spectrum in a broad range of i

  35. Slide 35: Appendix

    APPENDIX © 2022 SAB BIOTHERAPEUTICS, INC.

  36. Slide 36: Multi-Pronged Business Strategy Powered by Novel Proprietary Platform

    Product Development of Pipeline Assets: Best-in-Class, First-in-Class & Unmet Needs Industry Partnering & Research Collaborations: Monoclonal Discovery & Polyclonal Development/Production Global Public Health Security: Emerging Infectious Disease & Biothreats Multi-Pronged Business Strategy Powered

  37. Slide 37: Intellectual Property

    Intellectual Property 11 © 2022 SAB BIOTHERAPEUTICS, INC.

  38. Slide 38: Scaled Infrastructure & Capacity: Tc Bovine & Plasma Production Facility

    Scaled Infrastructure & Capacity: Tc Bovine & Plasma Production Facility 38 © 2022 SAB BIOTHERAPEUTICS, INC.

  39. Slide 39: Scaled Infrastructure & Capacity: Laboratory & Manufacturing

    Scaled Infrastructure & Capacity: Laboratory & Manufacturing Manufacturing Facility (200L) Manufacturing Facility (50L) 39 CET Lab Labeling Suite Fill Suite Cell Culture Lab 50L Suite © 2022 SAB BIOTHERAPEUTICS, INC.

SAB Biotherapeutics — Investor Presentation (September 2022) on 6ix